Benitec Biopharma Inc.
BNTCHealthcare|Biotechnology|US
$9.54
+0.90 (+10.42%)
DCF Value
$2.63
Tangible Book / Share
$3.80
Cash / Share
$3.87
About
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Stock Price
-20.5%(1Y)
1M
+9.0%
3M
-30.0%
6M
-22.3%
YTD
-29.2%
1Y
-26.0%
3Y
+172.6%
5Y
-84.4%
Pipeline Summary
2 total trials1
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Completed: 1Recruiting: 1
Active Trials (1)
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
NCT06185673Oculopharyngeal Muscular Dystrophy
Phase 1Phase 2Recruiting
Enrollment: 30 participants
Key Facts
Market Cap$332.8M
Employees24 (+26% YoY)
CEOJerel A. Banks
IPO DateJun 24, 2014
Beta0.25
52-Week Range$7.885 – $14.39
Avg Volume158,589
ExchangeNASDAQ
Websitebenitec.com
Ownership
Float97.5%
Shares Outstanding34.9M
Recent Insider Trades
BUCHI J KEVINGIFT
Jun 29, 202651,813 shares
Friedman David MatthewAWARD
May 26, 202635,000 shares @ $11.45
Friedman David MatthewOTHER
May 22, 20260 shares
Mates SharonAWARD
Jan 22, 202631,500 shares @ $12.83
SUVRETTA CAPITAL MANAGEMENT, LLCBUY
Dec 29, 202565,800 shares @ $13.44
Peers
Recent News
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
Oct 28, 2026 · globenewswire.com
Benitec Biopharma (NASDAQ:BNTC) Share Price Breaks Below 50-Day Moving Average – Here’s What Happened
Oct 20, 2026 · defenseworld.net
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Oct 5, 2026 · globenewswire.com
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s Why
Sep 30, 2026 · defenseworld.net
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Sep 25, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:00 AM